The Long-Acting Dopamine Receptor Agonist Cabergoline in Early Parkinsons Disease: Final Results of a 5-Year, Double-Blind, Levodopa-Controlled Study

Author： Fulvio Bracco

Publisher： Adis International

ISSN： 1172-7047

Source： CNS Drugs, Vol.18, Iss.11, 2004-01, pp. : 733-746

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Importance of Within Subject Variation in Levodopa Pharmacokinetics: A 4Year Cohort Study in Parkinson’s Disease

By Chan Phylinda Nutt John Holford Nicholas

Journal of Pharmacokinetics and Pharmacodynamics, Vol. 32, Iss. 3-4, 2005-08 ,pp. : 307-331

Springer Publishing Company

Access to resources Recommend Favorite

Alternatives to Levodopa in the Initial Treatment of Early Parkinsons Disease

By Lees Andrew

Drugs & Aging, Vol. 22, Iss. 9, 2005-01 ,pp. : 731-740

Adis International

Access to resources Recommend Favorite

A Double-Blind, Placebo-Controlled Study of the Tolerability and Efficacy of a New Kappa-Opioid Receptor Agonist (R-84760) in Patients with Pain after Dental Surgery

By Seymour R.A.

Clinical Drug Investigation, Vol. 20, Iss. 6, 2000-12 ,pp. : 409-414

Adis International

Access to resources Recommend Favorite

Dopamine agonists in Parkinson’s disease

By Tintner Ron Jankovic Joseph

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 11, 2003-11 ,pp. : 1803-1820

Informa Healthcare

Access to resources Recommend Favorite

Cabergoline, Pramipexole and Ropinirole Used as Monotherapy in Early Parkinsons Disease: An Evidence-Based Comparison

By Inzelberg R. Schechtman E.

Drugs & Aging, Vol. 20, Iss. 11, 2003-01 ,pp. : 847-855

Adis International

Access to resources Recommend Favorite